CLIN.L Stock
Price Chart
CLIN.L Financial and Trading Overview
stock price | |
Previous Close | 924 |
Open | 924 |
Bid | 0 x 0 |
Ask | 0 x 0 |
Day's Range | 924 - 925 |
52 Week Range | 9.25 - 948.05 |
Volume | 1.79M |
Avg. Volume | 1.68M |
Market Cap | 1.23B |
Beta (5Y Monthly) | 1.467279 |
PE Ratio (TTM) | 41.47982 |
EPS (TTM) | 0 |
Forward Dividend & Yield | 0.08 (0.82%) |
Ex-Dividend Date | December 2, 2021 |
1y Target Est | 795.55 |
CLIN.L Valuation Measures
Enterprise Value | 1.57B |
Trailing P/E | 41.47982 |
Forward P/E | 0.35950252 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.3560824 |
Price/Book (mrq) | 275.2157 |
Enterprise Value/Revenue | 2.992 |
Enterprise Value/EBITDA | 14.52 |
Trading Information
Stock Price History
Beta (5Y Monthly) | 1.467279 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 948.05 |
52 Week Low | 9.25 |
50-Day Moving Average | 899.45 |
200-Day Moving Average | 745.26 |
CLIN.L Share Statistics
Avg. Volume (3 month) | 1.68M |
Avg. Daily Volume (10-Days) | 1.15M |
Shares Outstanding | 133.37M |
Float | 110.77M |
Short Ratio | N/A |
% Held by Insiders | 11.82% |
% Held by Institutions | 70.89% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.076 |
Trailing Annual Dividend Yield | 0.0082% |
5 Year Average Dividend Yield | 75.00% |
Payout Ratio | 0.2606 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2021 |
Most Recent Quarter (mrq) | June 30, 2021 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 5.78% |
Operating Margin (ttm) | 11.19% |
Gross Margin | 37.81% |
EBITDA Margin | 20.60% |
Management Effectiveness
Return on Assets (ttm) | 3.31% |
Return on Equity (ttm) | 8.89% |
Income Statement
Revenue (ttm) | 523.6M |
Revenue Per Share (ttm) | 3.94 |
Quarterly Revenue Growth (yoy) | 19.10% |
Gross Profit (ttm) | 198M |
EBITDA | 107.9M |
Net Income Avi to Common (ttm) | 39.7M |
Diluted EPS (ttm) | 22.3 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 82.9M |
Total Cash Per Share (mrq) | 0.62 |
Total Debt (mrq) | 418.7M |
Total Debt/Equity (mrq) | 93.67 |
Current Ratio (mrq) | 1.752 |
Book Value Per Share (mrq) | 3.361 |
Cash Flow Statement
Operating Cash Flow (ttm) | 45.2M |
Levered Free Cash Flow (ttm) | -17450000 |
Profile of
Country | |
State | N/A |
City | Burton Upon Trent |
Address | Pitcairn House |
ZIP | DE14 2WW |
Phone | 44 1283 495 010 |
Website | https://www.clinigengroup.com |
Industry | Medical Distribution |
Sector(s) | Healthcare |
Full Time Employees | 1069 |
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Q&A For Stock
What is a current CLIN.L stock price?
CLIN.L stock price today per share is .
How to purchase stock?
You can buy CLIN.L shares on the exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ?
The stock symbol or ticker of is CLIN.L.
Which industry does the company belong to?
The industry is Medical Distribution.
How many shares does have in circulation?
The max supply of shares is 0.
What is Price to Earnings Ratio (PE Ratio)?
PE Ratio is 0.00000000 now.
What was earnings per share over the trailing 12 months (TTM)?
EPS is 0 over the trailing 12 months.
Which sector does the company belong to?
The sector is Healthcare.
CLIN.L included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
FTSE AIM All-Share Index FTAI | 755.91 GBP 966.76 USD |
-0.38
|
— — | 755.91 GBP 966.76 USD | 763.17 GBP 976.05 USD | — - | — — |
- {{ link.label }} {{link}}